Immunotherapy for Prostate Cancer Enters Its Golden Age
نویسندگان
چکیده
In the United States, prostate cancer is the most frequent malignancy in men and ranks second in terms of mortality. Although recurrent or metastatic disease can be managed initially with androgen ablation, most patients eventually develop castration-resistant disease within a number of years, for which conventional treatments (eg, chemotherapy) provide only modest benefits. In the last few years, immunotherapy has emerged as an exciting therapeutic modality for advanced prostate cancer, and this field is evolving rapidly. Encouragingly, the US Food and Drug Administration (FDA) has recently approved two novel immunotherapy agents for patients with advanced cancer: the antigen presenting cell-based product sipuleucel-T and the anti-CTLA4 (cytotoxic T-lymphocyte antigen 4) antibody ipilimumab, based on improvements in overall survival in patients with castration-resistant prostate cancer and metastatic melanoma, respectively. Currently, a number of trials are investigating the role of various immunological approaches for the treatment of prostate cancer, many of them with early indications of success. As immunotherapy for prostate cancer enters its golden age, the challenge of the future will be to design rational combinations of immunotherapy agents with each other or with other standard prostate cancer treatments in an effort to improve patient outcomes further.
منابع مشابه
اثر ایمونوتراپی سرطان پروستات بر بیان ژنesp انتروکوکوس فکالیس
Background: Prostate cancer is the most commonly diagnosed malignancy and the second leading cause of cancer deaths among men in the world. Immunotherapy is a new, non-invasive and effective method for the treatment of cancer, but its side effects on the normal flora of bacteria and opportunistic infections not known yet. The aim of this study was to evaluate the effects of immunotherapy on Ent...
متن کاملStudy of NGEP expression in androgen sensitive prostate cancer cells: A potential target for immunotherapy
Background: Prostate cancer is one of the leading causes of cancer deaths among men. New gene expressed in prostate (NGEP), is a prostate-specific gene expressed only in normal prostate and prostate cancer tissue. Because of its selective expression in prostate cancer cell surface, NGEP is a potential immunotherapeutic target. To target the NGEP in prostate cancer, it is essential to investig...
متن کاملبررسی میزان آنتیژن اختصاصی پروستات در مردان سالم 40 تا 80 ساله شهر بیرجند
Background and Aim: Prostate cancer is one of the most prevalent type of cancer and the second cause of death among American men. Its prevalence has a direct relationship with increasing age. The present study was carried out to determine the level of prostate specific antigen (PSA) in Birjandi males aged between 40 and 80 years. Material and Methods: In this prospective study, out of 62...
متن کاملA Systematic Review of Clinical Practice Guidelines for Castration-Resistant Prostate Cancer
Cancer constitutes a huge burden on societies in countries with any level of economic development. Prostate cancer is the first most diagnosed cancer of men in developed countries and the forth one in developing countries in terms of incidence rate. It is also the third incident cancer of men in Iran along with a prevalence of about 10,000 cases. Castration-resistant prostate cancer (CRPC) is a...
متن کاملA Systematic Review of Clinical Practice Guidelines for Castration-Resistant Prostate Cancer
Cancer constitutes a huge burden on societies in countries with any level of economic development. Prostate cancer is the first most diagnosed cancer of men in developed countries and the forth one in developing countries in terms of incidence rate. It is also the third incident cancer of men in Iran along with a prevalence of about 10,000 cases. Castration-resistant prostate cancer (CRPC) is a...
متن کامل